Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

UPDATE 3-Australian coronavirus antibody therapy aims for trial in early 2021

Published 26/08/2020, 10:46 am
© Shutterstock
CSL
-

(Adds Australia Asia-Pacific vaccine commitment, total case counts for Australia, NZ)

By Renju Jose and Sonali Paul

SYDNEY/MELBOURNE, Aug 26 (Reuters) - Australian researchers hope to start human trials of a coronavirus antibody therapy in early 2021, while a large-scale trial of a vaccine could begin by the end of this year, scientists said on Wednesday.

The research targets came as the country's virus hotspot, Victoria state, recorded its second-most deadly day of the pandemic with 24 deaths. Just 156 new cases were reported nationwide on Wednesday, mostly in Victoria, well down from daily rises of more than 700 about three weeks ago.

Melbourne's Walter and Eliza Hall Institute has made good progress in identifying the most potent antibodies that could neutralise the spike protein on the virus that causes COVID-19, stopping it from being able to enter human cells, researcher Wai-Hong Tam said.

Antibody therapies would be most useful for the elderly and people with weakened immune systems, she said.

Almost 64% of Australia's 549 deaths from COVID-19 have occurred among residents of aged-care homes, mostly in Victoria.

"If we're very hopeful, we are looking at clinical trials early next year," Tam told reporters.

Separately, the University of Queensland said its scientists had reported to the International Society for Vaccines that their "molecular clamp" vaccine had been found to be effective in hamsters and could be manufactured at scale.

Assuming the team's ongoing phase 1 clinical trial shows adequate safety and immune responses, its partner, CSL Ltd CSL.AX , could start a large-scale study before the end of this year, UQ project co-leader Keith Chappell said.

The "molecular clamp" technology adds a gene to viral proteins to stabilise them and trick the body into thinking it is seeing a live virus so it makes antibodies against it.

The Australian government meanwhile committed A$80 million to ensure Southeast Asian and Pacific nations would have affordable access to any COVID-19 vaccines.

STATE OF EMERGENCY

With new cases declining, Victoria's government has come under fire for seeking to extend a state of emergency by another year. Premier Daniel Andrews said the government needed the legal certainty to be able to set restrictions, which would be the "lightest touch possible" while the economy reopens.

"The opening up process and the repair work will not be quick. It will take time," Andrews told reporters.

To help the national economic recovery, Prime Minister Scott Morrison announced a A$1 billion ($719 million) investment to boost the defence industry. L4N2FS0O1

Australia's total COVID-19 cases rose to 25,205, with 549 deaths, much lower than most other developed nations on a per-capita basis.

Neigbouring New Zealand, which extended a lockdown in its biggest city Auckland this week to contain an outbreak, reported five new cases, for a total of 1,344 cases.

($1 = 1.3906 Australian dollars)

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ FACTBOX-Latest on the worldwide spread of coronavirus

FACTBOX-Worldwide coronavirus cases cross 23.77 million, death toll at 814,072

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.